IndieBio

NanoPlume is a biomaterial manufacturer specializing in the large-scale production of innovative, eco-friendly biomaterials, notably Bio-Aerogel. The company focuses on creating advanced insulating biomaterials and aerogels, aiming to enhance energy and space efficiency, as well as promote circularity across various industries. By utilizing organic and recycled feedstocks and green technology, NanoPlume reduces waste and minimizes energy consumption. Its products are designed to insulate cargo boxes in the cold chain healthcare logistics sector, reducing payload and energy consumption, and extending battery range.

Minutia is a biotechnology company focused on developing innovative stem cell-derived transplants aimed at treating Type 1 Diabetes. The company specializes in creating insulin-producing cell transplants that incorporate proprietary nanosensors, allowing for real-time monitoring of transplant status. These immune-evasive cells are designed for subcutaneous implantation, addressing common challenges associated with transplant procedures. By advancing this technology, Minutia seeks to transform the clinical landscape for diabetes management and cell replacement therapies, ultimately working towards a functional cure for this condition.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Gozen Bioworks offers solutions and biomaterials developed with a biomimicry approach by combining science, art, philosophy, and design to raise awareness and provide help to the planet, living creatures, and humanity. They develop and invent high-performance microbe-derived materials from natural inputs, such as next-generation leather, biotextiles, bioplastics, packaging, and interior materials.

Unibaio specializes in biodegradable nano-encapsulation technology designed to optimize the delivery of agrochemicals, thereby reducing the need for harmful chemicals in pesticide formulations. The company's innovative particles enable pesticide manufacturers to comply with stringent environmental regulations while maintaining effective chemical use. Unibaio's technology enhances the uptake of fertilizers and pesticides, minimizing runoff and lowering application doses, which ultimately decreases costs for farmers. By utilizing natural compounds such as shrimp waste and clay, Unibaio adheres to a circular model in producing its micro-nanocapsules. This approach supports the development of both traditional and organic agricultural products, improving yield and competitiveness in the sector while promoting the health and well-being of crops.

Gozen Bioworks offers solutions and biomaterials developed with a biomimicry approach by combining science, art, philosophy, and design to raise awareness and provide help to the planet, living creatures, and humanity. They develop and invent high-performance microbe-derived materials from natural inputs, such as next-generation leather, biotextiles, bioplastics, packaging, and interior materials.

Vader Nanotechnologies focuses on developing innovative organisms and enzymes aimed at addressing environmental challenges, particularly in recycling plastics and degrading persistent chemicals like PFAS. The company employs advanced techniques such as automation, image processing, computer vision, and analytical chemistry to identify and optimize strains capable of thriving on these difficult-to-break-down substances. By utilizing directed evolution methods, Vader enhances the performance of these organisms, contributing to solutions that tackle pressing environmental and health issues.

BioFeyn is a company focused on enhancing the diet of farmed fish to boost health and sustainability in aquaculture. By optimizing marine ingredients, BioFeyn enables fish to receive nutrients akin to those found in their natural ocean habitat, resulting in improved efficiency across the industry. The company employs a specialized method of biodegradable nanoencapsulation, which surrounds trace amounts of marine ingredients with a shell of naturally-derived compounds. This innovative approach enhances digestion, absorption, and the bioavailability of nutrients, ensuring effective delivery to target tissues in the fish. Ultimately, BioFeyn's solutions aim to produce healthier fish while minimizing environmental impact, making the practice of consuming farmed fish more sustainable and nutritious for consumers.

Kraken Sense is a developer of an automated pathogen detection platform that utilizes advanced nanotechnology and real-time quantitative polymerase chain reaction (qPCR) technology. The company's innovative solution features autonomous sampling capabilities and cloud-based encryption, allowing for the detection of bacterial contamination across various sources, including liquids, solids, and aerosols. Kraken Sense's IoT-enabled dashboard and analytics tools facilitate low-cost and user-friendly monitoring, empowering clients to identify a wide range of biological and chemical entities in real time. Through its cutting-edge technology, Kraken Sense aims to enhance safety and efficiency in pathogen detection for diverse applications.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Dahlia Biosciences is a biotechnology company founded in 2011 and headquartered in California, United States. It specializes in DNA analysis and diagnostics, focusing on the development of RNA detection tools that facilitate precision medicine research. The company's innovative solutions utilize CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly within cells and tissues. This capability allows researchers to study and isolate cells with high resolution, significantly enhancing the sensitivity and robustness of RNA detection in various applications. Dahlia Biosciences aims to advance research and diagnostic capabilities in the life sciences through its cutting-edge technologies.

Dahlia Biosciences is a biotechnology company founded in 2011 and headquartered in California, United States. It specializes in DNA analysis and diagnostics, focusing on the development of RNA detection tools that facilitate precision medicine research. The company's innovative solutions utilize CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly within cells and tissues. This capability allows researchers to study and isolate cells with high resolution, significantly enhancing the sensitivity and robustness of RNA detection in various applications. Dahlia Biosciences aims to advance research and diagnostic capabilities in the life sciences through its cutting-edge technologies.

Dahlia Biosciences is a biotechnology company founded in 2011 and headquartered in California, United States. It specializes in DNA analysis and diagnostics, focusing on the development of RNA detection tools that facilitate precision medicine research. The company's innovative solutions utilize CRISPR-Cas9 technology to detect multiple DNA and RNA biomarkers directly within cells and tissues. This capability allows researchers to study and isolate cells with high resolution, significantly enhancing the sensitivity and robustness of RNA detection in various applications. Dahlia Biosciences aims to advance research and diagnostic capabilities in the life sciences through its cutting-edge technologies.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

Catalog Technologies Inc. specializes in a DNA-based platform that revolutionizes digital data storage and computation. Founded in 2016 and headquartered in Boston, Massachusetts, the company provides a method for encoding digital information into DNA, making it a viable and cost-effective solution for long-term data archiving. By leveraging advanced synthetic biology technologies, Catalog aims to transform how information is stored, allowing customers to utilize DNA molecules as a primary medium for digital records. This innovative approach positions Catalog at the forefront of next-generation data storage solutions.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is dedicated to improving reconstruction options for breast cancer patients post-mastectomy. The company specializes in developing tissue-engineered nipple-areolar complex (NAC) grafts, which are designed to be used during the breast reconstruction phase. These off-the-shelf, acellular NAC grafts serve as a framework for the patient's own cells to regenerate their nipple and areola, providing a more natural outcome. The company is based in New Orleans, Louisiana.

ViaeX Technologies Inc. specializes in the development and manufacturing of bio-engineered nano-membrane technology solutions aimed at purifying water and air. The company's innovative biological nanofiltration systems are designed to be 400% more efficient than conventional methods, targeting specific pollutants and bacteria. These systems are biodegradable, cost-effective, and easily scalable, making them suitable for rapid deployment in cities facing significant pollution challenges. ViaeX's focus is on creating energy-efficient and environmentally friendly filtration systems that cater to industrial and municipal needs. The company's technological advancements are grounded in extensive research conducted at UC Berkeley and UC San Diego, utilizing breakthroughs in physical chemistry and nanotechnology. Additionally, ViaeX is developing sustainable nanomaterials from bio-waste, which can be applied across various industries, including water purification and food filtration, thereby reducing dependency on traditional materials and contributing to a more sustainable future.

Vali Nanomedical Corporation is a biotechnology company established in 2013 and headquartered in Los Angeles, California. The company specializes in developing a multidrug-delivery platform that utilizes proprietary nanoparticles with unique multilayered structures. This innovative technology enables a single nanoparticle to transport multiple drugs to tumors simultaneously, facilitating advanced cancer combination therapies that were previously unattainable. Vali's approach aims to enhance the specificity, efficacy, and safety of cancer treatments, offering healthcare providers new opportunities in the fight against cancer.

ViaeX Technologies Inc. specializes in the development and manufacturing of bio-engineered nano-membrane technology solutions aimed at purifying water and air. The company's innovative biological nanofiltration systems are designed to be 400% more efficient than conventional methods, targeting specific pollutants and bacteria. These systems are biodegradable, cost-effective, and easily scalable, making them suitable for rapid deployment in cities facing significant pollution challenges. ViaeX's focus is on creating energy-efficient and environmentally friendly filtration systems that cater to industrial and municipal needs. The company's technological advancements are grounded in extensive research conducted at UC Berkeley and UC San Diego, utilizing breakthroughs in physical chemistry and nanotechnology. Additionally, ViaeX is developing sustainable nanomaterials from bio-waste, which can be applied across various industries, including water purification and food filtration, thereby reducing dependency on traditional materials and contributing to a more sustainable future.

Vali Nanomedical Corporation is a biotechnology company established in 2013 and headquartered in Los Angeles, California. The company specializes in developing a multidrug-delivery platform that utilizes proprietary nanoparticles with unique multilayered structures. This innovative technology enables a single nanoparticle to transport multiple drugs to tumors simultaneously, facilitating advanced cancer combination therapies that were previously unattainable. Vali's approach aims to enhance the specificity, efficacy, and safety of cancer treatments, offering healthcare providers new opportunities in the fight against cancer.